… -mutations can benefit from EGFR-TKIs plus chemotherapy. In our research, we collected
information on patients who used EGFR-TKIs plus chemotherapy and TKIs alone … co-mutations, …

… and EGFR-TKIs vs chemotherapy or EGFR-TKIs alone in … alone in the treatment of advanced
NSCLC. Otherwise, all the participants in this study had the positive EGFR mutation gene, …

… patients with EGFR mutant NSCLC treated with EGFR-tyrosine kinase inhibitors (TKI) and
… Randomized phase III studies comparing other EGFR-TKIs alone or in combination with …

… plus chemotherapy reported promising efficacy and survival improvement compared to
EGFR-TKI and chemotherapy alone in EGFR-mutated NSCLC patients. They concluded that the …

… to EGFR TKIs resulted in even worse survival than TKIs alone in patients with BM and EGFR
mutations. … resulted in survival similar to that with chemotherapy alone in patients with BM. …

… among EGFR-mutant patients was relatively low prior to EGFR TKI … EGFR TKI alone. However,
only few immune checkpoint inhibitors have been studied as combination with EGFR TKIs …

… EGFR-TKI alone or in combination with chemotherapy in patients with low-abundance EGFR
mutations … effective treatment strategies for patients with low-abundance EGFR mutations. …

… Finally, eight studies comparing EGFR-TKI plus chemotherapy with EGFR-TKI alone as
first-line treatment in advanced non-small cell lung cancer with activating EGFR mutation were …

… response to EGFR-tyrosine kinase inhibitors (TKIs). … of EGFR-TKIs plus chemotherapy
versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations …

… This study was mainly focused on the comparison of clinical efficacy between EGFR-TKIs
plus brain RT and EGFR-TKIs alone in EGFR mutant NSCLC patients with BM. And furtherly …